International Journal of Cancer Management

Published by: Kowsar

Significance of EGFR mRNA Expression in Luminal and Triple Negative Breast Tumors

Farzaneh Darbeheshti 1 , Pantea Izadi 1 , * , Amir Nader Emami Razavi 2 , Fatemeh Kamali 2 , Mir Saeed Yekaninejad 3 and Javad Tavakkoly Bazzaz 1
Authors Information
1 Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
2 Iran National Tumor Bank, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of Cancer Management: February 2018, 11 (2); e9763
  • Published Online: February 28, 2018
  • Article Type: Research Article
  • Received: November 22, 2016
  • Revised: February 5, 2017
  • Accepted: February 21, 2018
  • DOI: 10.5812/ijcm.9763

To Cite: Darbeheshti F, Izadi P, Emami Razavi A N, Kamali F, Yekaninejad M S, et al. Significance of EGFR mRNA Expression in Luminal and Triple Negative Breast Tumors, Int J Cancer Manag. 2018 ; 11(2):e9763. doi: 10.5812/ijcm.9763.

Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. [PubMed: 25220842].
  • 2. Rafiemanesh H, Salehiniya H, Lotfi Z. Breast Cancer in Iranian Woman: Incidence by Age Group, Morphology and Trends. Asian Pac J Cancer Prev. 2016;17(3):1393-7. [PubMed: 27039778].
  • 3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-23. doi: 10.1073/pnas.0932692100. [PubMed: 12829800].
  • 4. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505-16. doi: 10.1038/nrm1962. [PubMed: 16829981].
  • 5. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem. 1989;34(1-6):123-31. [PubMed: 2576295].
  • 6. Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27(9):1212-22. doi: 10.1038/modpathol.2013.251. [PubMed: 24406864].
  • 7. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res. 2001;7(7):1850-5. [PubMed: 11448895].
  • 8. Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 2012;36(5):490-6. doi: 10.1016/j.canep.2012.06.005. [PubMed: 22818908].
  • 9. Gutteridge E, Agrawal A, Nicholson R, Cheung KL, Robertson J, Gee J. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. Int J Cancer. 2010;126(8):1806-16. doi: 10.1002/ijc.24884. [PubMed: 19739079].
  • 10. Deng M, Wang J, Chen Y, Zhang L, Liu D. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Anticancer Drugs. 2015;26(4):422-7. doi: 10.1097/CAD.0000000000000202. [PubMed: 25588160].
  • 11. Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int. 2015;2015:357485. doi: 10.1155/2015/357485. [PubMed: 25695063].
  • 12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi: 10.1006/meth.2001.1262. [PubMed: 11846609].
  • 13. Meseure D, Vacher S, Drak Alsibai K, Trassard M, Susini A, Le Ray C, et al. Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: a candidate biomarker to predict EGFR inhibitor effectiveness. Int J Cancer. 2012;131(4):1009-10. doi: 10.1002/ijc.26434. [PubMed: 21918978].
  • 14. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20(5):862-7. doi: 10.1093/annonc/mdn710. [PubMed: 19150933].
  • 15. Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, et al. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med. 2012;10 Suppl 1. S4. doi: 10.1186/1479-5876-10-S1-S4. [PubMed: 23046633].
  • 16. Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol. 1985;38(11):1225-8. [PubMed: 2999195].
  • 17. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1(8547):1398-402. [PubMed: 2884496].
  • 18. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002;8(11):3454-60. [PubMed: 12429634].
  • 19. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005;104(4):676-81. doi: 10.1002/cncr.21217. [PubMed: 15981280].
  • 20. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116(2):317-28. doi: 10.1007/s10549-008-0206-z. [PubMed: 18839307].
  • 21. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res. 2008;10(3):R49. doi: 10.1186/bcr2103. [PubMed: 18522728].
  • 22. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat. 1994;29(1):117-25. [PubMed: 7912565].
  • 23. Nozoe T, Mori E, Iguchi T, Egashira A, Adachi E, Matsukuma A, et al. Immunohistochemical expression of epidermal growth factor receptor in breast cancer. Breast Cancer. 2011;18(1):37-41. doi: 10.1007/s12282-010-0200-2. [PubMed: 20204554].
  • 24. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J, et al. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer. 2014;21(1):66-74. doi: 10.1007/s12282-012-0354-1. [PubMed: 22481575].
  • 25. Sobande F, Dusek L, Matejkova A, Rozkos T, Laco J, Ryska A. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Cesk Patol. 2015;51(2):80-6. [PubMed: 25970719].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments